Scribe Therapeutics
Latest round
- Series B
Last raised
- Mar 2021
Total raised
- $120M
Investors
- 9
About Scribe Therapeutics
Scribe Therapeutics, Inc.Scribe Therapeutics, Inc. is dedicated to developing advanced CRISPR technologies for therapeutic applications. Founded in 2018 by Benjamin Oakes and Brett Staahl, the company is headquartered in Alameda, California, US. Rowe Price.Scribe Therapeutics focuses on developing innovative CRISPR-based therapeutics to tackle significant genetic health challenges, especially cardiometabolic diseases, which are a leading global cause of death. Their offerings include CRISPR technologies that aim to provide safe and effective solutions for a variety of diseases. The company emphasizes molecular engineering to ensure the safety and specificity of its CRISPR systems, addressing both inherited and chronic conditions.Scribe Therapeutics generates revenue primarily through strategic partnerships with pharmaceutical companies and collaborative agreements for the research and development of CRISPR-based therapies. The company engages in B2B transactions, working with larger entities on the development and commercialization of therapeutic products.00 mn in March 2021, Scribe Therapeutics plans to utilize these resources to further develop its gene editing and delivery technologies. The company is focused on advancing a pipeline of therapeutics for neurodegeneration and other diseases. Scribe Therapeutics aims to expand its market reach beyond current territories, with specific plans to enter additional markets in North America and Europe by 2023, thereby broadening its impact on global health challenges.
Who invested in Scribe Therapeutics
9 investors across 2 rounds
See all investors in Scribe Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Scribe Therapeutics
Who invested in Scribe Therapeutics?
Scribe Therapeutics has 9 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Scribe Therapeutics raised?
Scribe Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Scribe Therapeutics last raise money?
Scribe Therapeutics's most recent round on record is a Series B, in Mar 2021.
What does Scribe Therapeutics do?
Scribe Therapeutics is a biotechnology company.
Where is Scribe Therapeutics headquartered?
Scribe Therapeutics is headquartered in Alameda, US.
Which VCs invest in companies like Scribe Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Scribe Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Scribe Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.